Skip to main content

Diabetes & Weight Loss News

Novo Nordisk’s Head of China Ron Christie divulges details on the state of diabetes care in the world’s most populous nation.
In previous issues, we’ve documented the arduous journey of Orexigen’s anti-obesity drug Contrave through the regulatory process. In December, an FDA Advisory Committee...
Larry Soler and Dr. James Gavin discuss Partnership for a Healthier America's efforts to fight childhood obesity.
Kelly reflects on her recent visit to Washington…
(S)he said what?!?
In late March, the International Diabetes Federation (IDF) released a "position statement" recommending the consideration of bariatric surgery to treat type 2 diabetes...
(S)he said what?!?
Puzzled by the recent FDA decisions? Dr. Sanjay Kaul discusses the regulatory environment for diabetes and obesity medications.
Kelly muses on the future of GLP-1 agonists and bariatric surgery.
Allergan’s LAP-BAND, an implantable weight-loss device. Following an FDA advisory committee ’s recommendation last December (see New Now Next in diaTribe #28), the FDA...
What can Type 1 University really teach you? See what type 1 maven Adam Brown has to say about Gary Scheiner's new brainchild.
The LAP-BAND is a weight-loss device that is implanted around the top of the stomach using minimally invasive (laparoscopic) surgery, which effectively creates a small...
After a day of deliberation earlier this month, a recent FDA advisory committee voted 13 to 7 to recommend approval of Contrave, a novel weight-loss drug made by...
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
A next gen weight management and fitness tool— type 1 patient Adam Brown shares his thoughts on BodyMedia’s FIT Weight Management System.
Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…
We recently reviewed three drug candidates for the treatment of obesity – Contrave, lorcaserin, and Qnexa. All three drugs in development: they all have been submitted...

Pages